NASDAQ: AXDX - Accelerate Diagnostics, Inc.

Yield per half year: -71.74%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Accelerate Diagnostics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

more details
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 1996-11-18
ISIN US00430H1023
Industry Life Sciences Tools & Services
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://acceleratediagnostics.com
Цена ао 0.8771
Change price per day: -1.65% (0.546)
Change price per week: -7.46% (0.5803)
Change price per month: -53.3% (1.15)
Change price per 3 month: -50.28% (1.08)
Change price per half year: -71.74% (1.9)
Change price per year: -40.99% (0.91)
Change price per 3 year: -51.18% (1.1)
Change price per 5 year: -93.88% (8.77)
Change price per year to date: -67.45% (1.65)
All parameters

Underestimation

Title Value Grade
P/S 2.29 6
P/BV -0.4782 0
P/E 0 0
EV/EBITDA -2.13 0
Total: 4.5

Efficiency

Title Value Grade
ROA, % -167.03 0
ROE, % 131.82 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -1.79 10
Total: 9.2

Growth impulse

Title Value Grade
Yield Revenue, % 4.45 1
Yield Ebitda, % -41.05 0
Yield EPS, % -84.62 0
Total: 0.2
More

Institutions Volume Share, %
Griffin Asset Management, Inc. 1219724 5.63
Vanguard Group Inc 306637 1.42
Birchview Capital, LP 225239 1.04
Cannell (Peter B.) & Company Inc 114690 0.53
Oracle Investment Management Inc 111575 0.52
Geode Capital Management, LLC 87003 0.4
Chartist, Inc. 68996 0.32
TCI Wealth Advisors, Inc. 58680 0.27
Blackrock Inc. 50842 0.23
Northern Trust Corporation 46119 0.21



Head Job title Payment Year of birth
Mr. Jack Phillips CEO, President & Director 595k 1966 (59 years)
Mr. Lawrence Michael Mertz Chief Technology Officer 335.94k 1963 (62 years)
Mr. David Patience Chief Financial Officer 285.27k 1986 (39 years)
Ms. Maya Gowri Senior VP & Head of Operations N/A
Laura Pierson Investor Relations Officer N/A
Mr. John Meduri Chief Strategy Officer N/A
Mr. Chris Thode Senior Vice President of US Commercial N/A
Ms. Rita Boukamel Senior VP & Head of EMEA N/A

Address: United States, Tucson. AZ, 3950 South Country Club Road - open in Google maps, open in Yandex maps
Website: https://acceleratediagnostics.com